BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 26573799)

  • 21. Positron emission tomography imaging with
    Kasten BB; Houson HA; Coleman JM; Leavenworth JW; Markert JM; Wu AM; Salazar F; Tavaré R; Massicano AVF; Gillespie GY; Lapi SE; Warram JM; Sorace AG
    Sci Rep; 2021 Jul; 11(1):15384. PubMed ID: 34321569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H
    Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE
    Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site-Specific Immuno-PET Tracer to Image PD-L1.
    Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
    Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.
    Mayer KE; Mall S; Yusufi N; Gosmann D; Steiger K; Russelli L; Bianchi HO; Audehm S; Wagner R; Bräunlein E; Stelzl A; Bassermann F; Weichert W; Weber W; Schwaiger M; D'Alessandria C; Krackhardt AM
    Theranostics; 2018; 8(21):6070-6087. PubMed ID: 30613283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity.
    Ko E; Luo W; Peng L; Wang X; Ferrone S
    Cancer Res; 2007 Aug; 67(16):7875-84. PubMed ID: 17699794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Perspectives on
    Yoon JK; Park BN; Ryu EK; An YS; Lee SJ
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560337
    [No Abstract]   [Full Text] [Related]  

  • 33. Preclinical development of ZED8, an
    Ogasawara A; Kiefer JR; Gill H; Chiang E; Sriraman S; Ferl GZ; Ziai J; Bohorquez SS; Guelman S; Wang X; Yang J; Phan MM; Nguyen V; Chung S; Yu C; Tinianow J; Waaijer SJH; De Crespigny A; Marik J; Boswell CA; Zabka T; Staflin K; Williams SP
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):287-301. PubMed ID: 36271158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.
    Houghton JL; Zeglis BM; Abdel-Atti D; Aggeler R; Sawada R; Agnew BJ; Scholz WW; Lewis JS
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15850-5. PubMed ID: 26668398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of cancer-specific CD8(+) CD69(+) cells inhibits colon cancer growth.
    Lan B; Zhang J; Lu D; Li W
    Immunobiology; 2016 Jan; 221(1):1-5. PubMed ID: 26314763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity.
    Yin P; Gui L; Wang C; Yan J; Liu M; Ji L; Wang Y; Ma B; Gao WQ
    Mol Ther; 2020 Dec; 28(12):2553-2563. PubMed ID: 32827461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.
    Tavaré R; McCracken MN; Zettlitz KA; Knowles SM; Salazar FB; Olafsen T; Witte ON; Wu AM
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1108-13. PubMed ID: 24390540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
    Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
    Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.